- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.06. | Odyssey Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 17.06. | Odyssey Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.06. | Odyssey Therapeutics Inc: Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | 483 | GlobeNewswire (Europe) | Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on... ► Artikel lesen | |
| ODYSSEY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 02.06. | Oppenheimer initiates Odyssey Therapeutics stock with outperform rating | 2 | Investing.com | ||
| 02.06. | TD Cowen initiates Odyssey Therapeutics stock at Buy on drug pipeline | 1 | Investing.com | ||
| 02.06. | JPMorgan initiates Odyssey Therapeutics stock rating at Overweight | 1 | Investing.com | ||
| 11.05. | Odyssey Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.05. | Odyssey Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 08.05. | Autoimmune diseases biotech Odyssey Therapeutics prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| 08.05. | Odyssey Therapeutics Prices Upsized IPO Of 15.50 Mln Shares At $18/shr | 701 | AFX News | WASHINGTON (dpa-AFX) - Odyssey Therapeutics Inc. announced the pricing of its upsized initial public offering of 15.50 million shares of common stock at $18.00 per share. The company has also... ► Artikel lesen | |
| 08.05. | Odyssey Therapeutics prices $304M IPO at $18 per share | 2 | Investing.com | ||
| 08.05. | Odyssey Therapeutics Inc: Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering | 199 | GlobeNewswire (Europe) | BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. ("Odyssey"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune... ► Artikel lesen | |
| 05.05. | Odyssey Therapeutics, Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 04.05. | Autoimmune diseases biotech Odyssey Therapeutics sets terms for $225 million IPO, pricing this week | 1 | Renaissance Capital | ||
| 04.05. | Odyssey Therapeutics, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 17.04. | Autoimmune diseases biotech Odyssey Therapeutics refiles for a $100 million IPO | 2 | Renaissance Capital | ||
| 17.04. | Odyssey Therapeutics, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 16.03. | Odyssey Therapeutics appoints H Martin Seidel to Scientific Advisory Board | 1 | PMLiVE | ||
| 21.01. | Odyssey Therapeutics Appoints Jolie Siegel EVP and General Counsel | 1 | Contract Pharma | ||
| 10.09.25 | Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs | 433 | GlobeNewswire (Europe) | Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,680 | +2,13 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| PALATIN TECHNOLOGIES | 10,930 | +6,63 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,320 | +10,18 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | -4,90 % | NurExone bringt Entwicklung, Finanzierung und US-Ausbau voran | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,450 | +2,73 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,918 | +6,71 % | RedHill Biopharma closes $6 million private placement | ||
| ONCO-INNOVATIONS | 0,469 | +0,86 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| NOVOCURE | 13,390 | +2,06 % | Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start... ► Artikel lesen | |
| PHARMING | 1,174 | +0,34 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,800 | +2,33 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| REVOLUTION MEDICINES | 156,10 | -0,35 % | Revolution Medicines, Inc.: Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic ... | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,840 | 0,00 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| PALISADE BIO | 1,835 | +1,94 % | Palisade Bio, Inc.: Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors | Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,946 | +2,79 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches | SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage company developing pelareorep, today announced initial data from... ► Artikel lesen | |
| OMEROS | 7,020 | -25,48 % | Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA | Omeros Corporation (Nasdaq: OMER) announced today an update on the review by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of the company's marketing... ► Artikel lesen |
Das Unternehmen ODYSSEY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,30 % bei einem Aktienkurs von 18,210 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ODYSSEY THERAPEUTICS INC finden Sie auf Wallstreet Online.